Antisense oligonucleotides which combat aberrant splicing and methods of using the same

• US 5,976,879 A
• Filed: 04/30/1999
• Issued: 11/02/1999
• Est. Priority Date: 05/11/1993
• Status: Expired due to Term

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Kole, Ryszard, Dominski, Zbigniew
• Primary Examiner(s): LeGuyader, John L.
• Application Number:
  US09/302,390
• Time in Patent Office: 186 Days
• Field of Search: 514/44, 435/6, 435/91.1, 435/375, 435/325, 536/23.1, 536/24.31, 536/24.5, 536/24.3
• US Class Current: 435/375
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/3521 Methyl

Abstract

A method of combatting aberrant splicing in a pre-mRNA molecule containing a mutation is disclosed. When present in the pre-mRNA, the mutation causes the pre-mRNA to splice incorrectly and produce an aberrant mRNA or mRNA fragment different from the mRNA ordinarily encoded by the pre-mRNA. The method comprises hybridizing an antisense oligonucleotide to the pre-mRNA molecule to create a duplex molecule under conditions which permit splicing. The antisense oligonucleotide is one which does not activate RNase H, and is selected to block a member of the aberrant set of splice elements created by the mutation so that the native intron is removed by splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for carrying out the method are also disclosed.

Claims

1. A method of combatting alternate splicing in a pre-mRNA molecule:

wherein said pre-mRNA molecule contains a first set of splice elements defining a first intron which is removed by splicing to produce a first mRNA molecule encoding a first protein;

and wherein said pre-mRNA further contains a second set of splice elements defining an alternate intron different from said first intron, which alternate intron is removed by splicing to produce an alternate second mRNA molecule different from said first mRNA molecule;

said method comprising;

hybridizing an antisense oligonucleotide to said pre-mRNA molecule to create a duplex molecule under conditions which permit splicing,

wherein said antisense oligonucleotide does not activate RNase H;

and wherein said oligonucleotide blocks a member of said alternate second set of splice elements;

so that said first intron is removed by splicing and said first mRNA molecule encoding a protein is produced.

2. The method according to claim 1, wherein said antisense oligonucleotide blocks a mutated splice element.

3. The method according to claim 1, wherein said antisense oligonucleotide blocks a native splice element.

4. The method according to claim 1, wherein said antisense oligonucleotide blocks a cryptic splice element.

5. The method according to claim 1, wherein said antisense oligonucleotide blocks a 5'"'"' splice site.

6. The method according to claim 1, wherein said antisense oligonucleotide blocks a 3'"'"' splice site.

7. The method according to claim 1, wherein said antisense oligonucleotide blocks a branch point.

8. The method according to claim 1, wherein said hybridizing step is carried out in a cell, and wherein said first mRNA is translated into said native protein.

9. The method according to claim 1, wherein said native protein is β

-globin.

10. The method according to claim 1, wherein said native protein is human β

-globin.

11. The method according to claim 1, wherein said antisense oligonucleotide is from 8 to 50 nucleotides in length.

12. The method according to claim 1, wherein said antisense oligonucleotide contains a modified internucleotide bridging phosphate residue selected from the group consisting of methyl phosphonates, methyl phosphonothioates, phosphoromorpholidates, phosphoropiperazidates, and phosphoramidates.

13. The method according to claim 1, wherein said antisense oligonucleotide contains a nucleotide having a loweralkyl substituent at the 2'"'"' position thereof.